Ascendis Pharma A/S Research And Development Expense in EUR from 2015 to 2024

Taxonomy & unit
ifrs-full: EUR
Summary
Ascendis Pharma A/S quarterly/annual Research And Development Expense history and growth rate from 2015 to 2024.
  • Ascendis Pharma A/S Research And Development Expense for the quarter ending September 30, 2024 was €73.5M, a 34% decline year-over-year.
  • Ascendis Pharma A/S annual Research And Development Expense for 2024 was €307M, a 25.7% decline from 2023.
  • Ascendis Pharma A/S annual Research And Development Expense for 2023 was €413M, a 8.91% increase from 2022.
  • Ascendis Pharma A/S annual Research And Development Expense for 2022 was €380M, a 28.3% increase from 2021.
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Growth (%)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Growth (%)

Ascendis Pharma A/S Quarterly Research And Development Expense (EUR)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 73.5M -37.9M -34% Jul 1, 2024 Sep 30, 2024 6-K 2024-11-14
Q1 2024 378M 70.7M -35.4M -33.4% Jan 1, 2024 Mar 31, 2024 6-K 2024-05-02
Q4 2023 413M 90.9M -17.7M -16.3% Oct 1, 2023 Dec 31, 2023 20-F 2025-02-12
Q3 2023 431M 111M +14M +14.4% Jul 1, 2023 Sep 30, 2023 6-K 2024-11-14
Q2 2023 417M 105M +14.6M +16.2% Apr 1, 2023 Jun 30, 2023 6-K 2023-09-05
Q1 2023 403M 106M +22.9M +27.6% Jan 1, 2023 Mar 31, 2023 6-K 2024-05-02
Q4 2022 380M 109M +43M +65.4% Oct 1, 2022 Dec 31, 2022 20-F 2025-02-12
Q3 2022 337M 97.4M +38.7M +65.8% Jul 1, 2022 Sep 30, 2022 6-K 2023-11-07
Q2 2022 298M 90.4M +7.08M +8.5% Apr 1, 2022 Jun 30, 2022 6-K 2023-09-05
Q1 2022 291M 83.2M -4.96M -5.62% Jan 1, 2022 Mar 31, 2022 6-K 2023-04-27
Q4 2021 296M 65.7M -10.1M -13.3% Oct 1, 2021 Dec 31, 2021 20-F 2024-02-07
Q3 2021 306M 58.8M -5.3M -8.27% Jul 1, 2021 Sep 30, 2021 6-K 2022-11-02
Q2 2021 311M 83.3M +19.7M +31% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-10
Q1 2021 292M 88.1M +30.6M +53.3% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-11
Q4 2020 261M 75.8M +25.5M +50.7% Oct 1, 2020 Dec 31, 2020 20-F 2023-02-16
Q3 2020 235M 64.1M +17.8M +38.5% Jul 1, 2020 Sep 30, 2020 6-K 2021-11-10
Q2 2020 218M 63.6M +19.8M +45.1% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-27
Q1 2020 198M 57.5M +6.26M +12.2% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-27
Q4 2019 192M 50.3M +12.3M +32.3% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-02
Q3 2019 179M 46.3M +14.7M +46.8% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-12
Q2 2019 165M 43.8M +3.59M +8.93% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-27
Q1 2019 161M 51.3M +20.7M +67.8% Jan 1, 2019 Mar 31, 2019 6-K 2020-05-19
Q4 2018 140M 38M +9.96M +35.5% Oct 1, 2018 Dec 31, 2018 20-F 2021-03-10
Q3 2018 130M 31.5M +2.44M +8.41% Jul 1, 2018 Sep 30, 2018 6-K 2019-11-18
Q2 2018 128M 40.2M +18.4M +83.9% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-28
Q1 2018 110M 30.5M +9.93M +48.2% Jan 1, 2018 Mar 31, 2018 6-K 2019-05-30
Q4 2017 99.6M 28M Oct 1, 2017 Dec 31, 2017 20-F 2020-04-03
Q3 2017 29.1M Jul 1, 2017 Sep 30, 2017 6-K 2018-11-28
Q2 2017 21.9M Apr 1, 2017 Jun 30, 2017 6-K 2018-08-29
Q1 2017 20.6M Jan 1, 2017 Mar 31, 2017 6-K 2018-05-30

Ascendis Pharma A/S Annual Research And Development Expense (EUR)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 307M -106M -25.7% Jan 1, 2024 Dec 31, 2024 20-F 2025-02-12
2023 413M +33.8M +8.91% Jan 1, 2023 Dec 31, 2023 20-F 2025-02-12
2022 380M +83.8M +28.3% Jan 1, 2022 Dec 31, 2022 20-F 2025-02-12
2021 296M +35M +13.4% Jan 1, 2021 Dec 31, 2021 20-F 2024-02-07
2020 261M +69.3M +36.2% Jan 1, 2020 Dec 31, 2020 20-F 2023-02-16
2019 192M +51.3M +36.6% Jan 1, 2019 Dec 31, 2019 20-F 2022-03-02
2018 140M +40.7M +40.9% Jan 1, 2018 Dec 31, 2018 20-F 2021-03-10
2017 99.6M +33.6M +50.8% Jan 1, 2017 Dec 31, 2017 20-F 2020-04-03
2016 66M +25.5M +62.9% Jan 1, 2016 Dec 31, 2016 20-F 2019-04-03
2015 40.5M Jan 1, 2015 Dec 31, 2015 20-F 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.